1 active not recruiting, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Terminated 1 |
Follow oregovomab: new trials by email Literature Review of oregovomab trials Research Report on oregovomab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| Clinical Trial for Ovarian Cancer (OvaRex®) oregovomab - Ovarian Cancer | Phase 3 | Terminated | Unither Pharmaceuticals | 354 | 2002-12-01 | 2007-12-18 |
Ovarian Neoplasms (2) · Carcinoma, Ovarian Epithelial (1) · Fallopian Tube Neoplasms (1) · Peritoneal Neoplasms (1)
CanariaBio Inc. (1) · Unither Pharmaceuticals (1)
United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · Czechia (1) · Hungary (1) · India (1) · Italy (1) · Mexico (1) · South Korea (1) · Spain (1) · Taiwan (1)